Articles tagged with Breast Cancer
A study published in Oncotarget found that physical activity can modulate miRNAs involved in breast cancer progression, leading to reduced cancer cell viability. The researchers identified two specific miRNAs, miR-206 and anti-miR-30c, which showed promising results as non-invasive biomarkers for breast cancer prevention.
Researchers at Tulane University discovered a way to inhibit aggressive triple negative breast cancer by targeting the TRAF3IP2 gene. Suppressing this gene suppresses tumor growth and metastasis, while silencing another gene, Rab27a, only delays tumor growth but not metastasis.
A study found that satisfied breast cancer survivors have lower psychological stress and inflammation, which can promote overall health. The research suggests that fostering healthy relationships is crucial for breast cancer patients' well-being during a stressful time.
Scientists have made a breakthrough discovery in understanding small cell lung cancer, finding that it can change and adapt to evade treatments. The study suggests that the tumor is like a 'moving target' that requires multiple treatments to be effective.
Research reveals that cancer clusters exhibit higher metastatic potential than single cells due to increased resistance to natural killer cell-mediated destruction. The study suggests enhancing the ability of activated NK cells to eliminate cluster metastasis could provide a complementary cancer therapy approach.
A WPI-led research team has identified drugs that target triple-negative breast cancer tumors in mice without inducing toxic side effects. The targeted therapies use molecular recognition units to specifically target the tumors, reducing their sizes and eliminating them.
A comprehensive survey reveals that bacteria are widespread in human tumors, differing by tumor type. Different tumor types harbor distinct microbiomes, with breast tumors displaying a rich and diverse community of bacteria.
The study profiles 14 subtypes of immune cells in 100 brain tumor samples and reveals five types that predominantly sculpt the brain TME. The researchers found distinct patterns of immune cell composition and function among different glioma subtypes, including low-grade and high-grade gliomas.
A phase 3 trial found that surgery and radiation after initial systemic therapy did not improve overall survival for women with stage IV breast cancer. The study suggests that these treatments should not be routine practice, instead focusing on proven therapies to prolong life.
A study by the Hubrecht Institute found that oviduct cells are more prone to develop into tumors than ovarian surface epithelium cells. This suggests a possible shift in treatment approach, with earlier removal of fallopian tubes considered as a preventive measure for high-risk patients.
Boosting the activity of tumor proteasomes could improve chemotherapy treatment outcomes and enhance immunotherapy for aggressive triple-negative breast cancer. Researchers analyzed 3,500 breast tumors to make this finding.
A new study by the University of Copenhagen's researchers has revealed that the protein PP2A inhibits cancer development in mice by turning off an enzyme called ADAM17. This finding has significant implications for understanding the role of PP2A as a tumour suppressor and exploring potential therapeutic applications.
A new technique, multi-spectral optoacoustic mesoscopy (MSOM), enables high-resolution visualization of tumor tissue patterns without the need for surgical biopsies. MSOM allows researchers to study blood supply patterns, oxygenation levels, and drug efficacy with greater accuracy.
Researchers have identified Creld2 as a key player in the development and growth of aggressive breast cancers. High levels of this protein are found in triple negative breast cancers, which have poor survival rates and are difficult to treat.
Researchers have developed a new combined treatment using a senescence inducer and a senolytic nanoparticle that selectively removes senescent cells, delaying tumor growth and reducing metastasis in aggressive breast cancer. The study provides new therapeutic methodologies to be developed in subsequent stages and clinical trials.
A study found that breast cancer survivors underutilize recommended strategies for reducing fatigue, despite high prevalence and persistence. The analysis also revealed differences in utilization of physical activity and supportive care depending on the type of fatigue experienced.
Researchers have created a high-performance cancer vaccine utilizing self-healing polylactic acid microcapsules, which efficiently activate the immune system and inhibit tumor growth. The vaccine achieves effective T cell response, potent tumor inhibition, and anti-metastatic effects in various tumor models.
Researchers identified two novel biomarkers, PDL1/CD274 copy number alteration and PD-L1 combined positive score, that correlate with improved outcomes in patients with metastatic breast cancer treated with immunotherapy. These biomarkers may help identify patients most likely to benefit from this treatment.
A comprehensive analysis of exercise and its protective role for high-risk breast cancer patients reveals that even a modest amount of exercise can be beneficial, reducing the risk of cancer recurrence by 55%, and death by 68%. The study found that starting exercise after treatment also offers significant survival benefits.
Researchers found that African American women have a higher risk of breast cancer due to shared genes with white women, including BRCA1, BRCA2, and PALB2. Current breast cancer testing panels can be used for African American women, increasing the chances of early detection and prevention.
A new study published in Radiology found that women with probably benign breast lesions (BI-RADS 3) should have six-month follow-up imaging surveillance. The study showed that 1.9% of these women were diagnosed with cancer within six months, with a higher risk of malignancy than those downgraded to BI-RADS 1 or 2.
A recent study has identified 32 new sites on the human genome where variations in DNA appear to alter the risks of getting specific subtypes of breast cancer. The analysis, covering over 266,000 women, may eventually improve the ability to predict breast cancer risks at a subtype level.
Researchers from SWOG will make 31 digital presentations at the ASCO20 Virtual Scientific Program, reporting on trials involving chemotherapy regimens, financial toxicity, and multiple myeloma treatments. The studies found that pre-surgery chemotherapy can be done safely and has good outcomes regardless of the drugs used.
Researchers at IRB Barcelona have identified CPEB2 as a crucial factor in the development of luminal breast cancer. The study found that CPEB2 is essential for protein synthesis after hormonal stimulation, leading to less cell proliferation and better prognosis in patients with low expression levels.
Researchers have identified a new breast cancer gene, RBBP8, that may explain why some young women develop the disease. The study found that mutations in this gene can lead to cancer by damaging DNA and increasing the risk of genetic variants.
A recent NIH-funded project explores how the fear of cancer recurrence affects the well-being and relationships of breast cancer patients and their spouses. The research team, led by Jean-Philippe Laurenceau, will focus on three main health behaviors that can be influenced by recurrence fears.
A new study by SWOG Cancer Research Network found that simple text reminders do not improve breast cancer hormone therapy adherence. The study enrolled 724 post-menopausal women and tested the effectiveness of brief, twice-weekly text messages reminding them to take their medication.
The EULAR 2020 study investigates the connection between breast cancer, anti-hormonal therapy, and rheumatoid arthritis. The results show that the risk of breast cancer in women with RA is lower than in women with healthy joints, and no association was found between anti-hormonal breast cancer prophylaxis and later RA.
This review article discusses the features of challenging cold tumors and potential approaches to transform them into hot tumors, which are more responsive to immunotherapy. The authors summarize current strategies for enhancing T cell trafficking and discuss the limitations of existing immunotherapeutic approaches.
Researchers have discovered that patients with breast cancer develop alterations in monocytes, a type of leukocyte, early in the disease course. This finding paves the way for enhanced diagnosis and treatment of breast cancer, potentially allowing for earlier identification of aggressive tumors and personalized immunotherapy strategies.
A new study by Mount Sinai researchers found that insulin resistance is a key factor mediating racial disparities in breast cancer prognosis. Black women with invasive breast cancer had higher rates of insulin resistance and more aggressive tumors than white women.
A Swedish study of over half a million women reveals that early mammography screening significantly lowers the rates of advanced and fatal breast cancers. The analysis found a 41% reduction in fatal breast cancers and a 25% reduction in advanced breast cancer cases among screened participants.
Researchers found that adding venetoclax to hormone therapy and CDK4/6 inhibitors can kill senescent cancer cells, potentially prolonging cancer response to therapy. The findings have underpinned a phase 1 clinical trial in Melbourne combining the treatments.
A new tumour sampling method, representative sequencing, accurately detects genetic alterations in tumours by collecting data from a well-mixed representation of the whole tumour. This method has been shown to be more consistent and accurate than current methods, with implications for personalized cancer treatment.
Researchers at University of Pennsylvania activate G protein-coupled estrogen receptor (GPER) in human and mouse pancreatic cancer models, inhibiting growth and making tumors more sensitive to immunotherapy. This approach may improve efficacy of existing treatments in a type where PD-1 inhibitors have been ineffective.
Researchers at Harvard's Wyss Institute have created disc-shaped particles that control macrophage behavior to slow tumor growth and metastasis in mice. The 'backpacks' keep macrophages in their tumor-killing state for up to five days, reducing the size of tumors and metastatic nodules.
A new study led by Yale Cancer Center researchers shows that immunotherapy prior to surgery can increase the rate of complete eradication of high-risk HER2-negative breast cancer from the breast and lymph nodes. The treatment combination of durvalumab, a checkpoint inhibitor, with chemotherapy resulted in a higher pCR rate compared to ...
Researchers at Walter and Eliza Hall Institute have discovered a new population of immune cells called ductal macrophages that play a crucial role in maintaining healthy breast tissue by clearing away dying milk-producing cells. This discovery could lead to new insights into treating breast cancer.
The Phase III EMBRACA trial found talazoparib improved patient-reported quality-of-life measures and had a tolerable safety profile in patients with metastatic HER2-negative breast cancer and BRCA1/2 mutations. However, the study did not demonstrate a statistically significant overall survival benefit due to subsequent treatments.
Researchers at DKFZ successfully blocked a receptor that stimulates tumor growth and metastasis with an antibody, slowing down cancer progression. The study found that the antibody reduced metastases in treated mice without affecting blood vessel formation.
A study by King's College London found that cancer patients referred by GPs with suspected cancer had lower mortality rates and were more likely to be diagnosed at an earlier stage for breast, lung, and prostate cancer. Early GP referrals have made a significant impact in improving cancer outcomes in the NHS.
A new imaging technique combining high-resolution imaging with quantitative measurement of tissue elasticity can detect cancer within resected margins of breast-conserving surgery. The study found QME to have high sensitivity and specificity for detecting cancer, reducing the need for additional surgeries.
Researchers have developed a unique immunotherapy delivery system that can turn cold tumors into 'hot' tumors, making it effective in cancers such as breast and melanoma. The system uses a protein called interleukin 12 to inflame the tumor and activate the immune system.
A new study has identified a molecular pathway responsible for the progression and spread of triple-negative breast cancer (TNBC). By blocking the signaling pathway, researchers found that tumors grew and spread more slowly. The findings suggest that patients with low ELF5 protein levels should be given interferon-gamma signaling-block...
Researchers describe a possible mechanism linking obesity and breast cancer, proposing that fatty acid binding protein (FABP4) drives tumor growth. Elevated FABP4 levels in obese individuals promote breast cancer development through direct interaction with cancer cells.
Researchers developed a new imaging technique, XDFI-CT, to visualize the 3D internal structure of the nipple. The study reveals three distinct types of duct arrangements and provides evidence for the 'sick lobe theory' that non-invasive breast cancer begins in a single mammary lobe.
A study of 950,000 cancer patients found differences in stage at diagnosis, therapy use, and overall survival by racial and ethnic groups. The analysis revealed disparities in cancer care across various ethnicities.
A systematic review and meta-analysis of prospective studies found that consuming a diet high in fiber was associated with a reduced incidence of breast cancer. The findings suggest that soluble fiber and higher total fiber intake are linked to lower risks of breast cancer, particularly in premenopausal and postmenopausal women.
A new study published in Cancer Research found that Indigenous American ancestry is associated with a greater incidence of HER2-positive breast cancer in Latinas. The study analyzed data from over 1,300 patients and found that women with higher proportions of IA ancestry were more likely to develop HER2-positive tumors.
A Swedish cohort study found that breast density, microcalcifications, and masses have a significant genetic component, with heritability estimates of 58%, 23%, and 13% respectively. The study also identified positive associations between these traits and genetic predisposition to breast cancer.
Researchers discovered that activating the androgen receptor decreases tumor growth in estrogen receptor-positive (ER+) breast cancer. The study used enobosarm, an androgen receptor-stimulating drug, which stopped tumor growth in all models tested.
A large observational study compared radiologists' recall rates and cancer detection in breast cancer screenings using digital breast tomosynthesis (DBT) and digital mammography. The study found that DBT had higher cancer detection rates but lower recall rates than digital mammography.
Researchers found that nanoparticles coated with trastuzumab were better retained in tumors and stimulated an anti-cancer immune response, even in HER2-negative tumors. The study suggests that the host's immune system plays a crucial role in determining nanoparticle retention and efficacy.
The study found that SRK-181 inhibits latent TGFβ1 activation with high selectivity and overcomes primary resistance to checkpoint blockade therapy by altering the tumor immune landscape. Preclinical results demonstrated improved preclinical safety profiles compared to conventional inhibitors of TGFβ signaling.
A team of researchers from Universities of Bonn and Ulm has investigated how a cell's proteasome can be programmed to degrade proteins that fuel cancer cell growth. By customizing molecular hybrids called PROTACs, they successfully targeted a protein essential for tumor cells to multiply.
In a phase I study, fam-trastuzumab deruxtecan-nxki (Enhertu) demonstrated clinical activity in patients with non-breast/non-gastric cancer types with HER2 overexpression or mutation. The overall objective response rate was 28.3 percent, with greatest response rates for NSCLC and HER2-mutant NSCLC.
Researchers have developed a new contrast agent that detects brain metastases in certain types of cancer, such as breast cancer, at an early stage using minimal amounts of contrast agent. The agent works by detecting the formation of new blood vessels, improving MRI sensitivity and visualization.
New research suggests that statin therapy may protect against heart damage caused by certain breast cancer therapies. A population-based study found a significantly lower risk of treatment-related heart failure among women taking statins while receiving anthracyclines or trastuzumab.
A new study found that the protein peptidyl arginine deiminase 4 (PAD4) promotes breast cancer metastasis in mice when expressed in cancer cells. PAD4 enables immune cells to trap bacteria, but its role in breast cancer has been unclear.
A new study benchmarks the technology, finding it effectively detects early arm swelling associated with lymphedema in breast cancer patients. The detection technology improves not only physical health but also peace of mind and finances.